These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 772721)

  • 1. 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome.
    Ungerstedt U
    Pharmacol Ther B; 1976; 2(1):37-40. PubMed ID: 772721
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiparkinsonian drugs and dopaminergic neostriatal mechanisms: studies in rats with unilateral 6-hydroxydopamine (=6-OH-DA)-induced degeneration of the nigro-neostriatal DA pathway and quantitative recording of rotational behaviour.
    Fuxe K; Ungerstedt U
    Pharmacol Ther B; 1976; 2(1):41-7. PubMed ID: 817332
    [No Abstract]   [Full Text] [Related]  

  • 3. Further evidence for the stimulation of rat brain dopamine receptors by ergometrine.
    Woodruff GN; Elkhawad AO; Crossman AR
    J Pharm Pharmacol; 1974 Jun; 26(6):455-6. PubMed ID: 4154992
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of chronic morphine treatment on dopamine-mediated turning behaviour in rats and mice with 6-hydroxydopamine-induced unilateral nigro-striatal lesions.
    Slater P; Crossman AR
    Neuropharmacology; 1980 Mar; 19(3):289-95. PubMed ID: 7191487
    [No Abstract]   [Full Text] [Related]  

  • 5. Circling behaviour induced by dopamine releasers and/or uptake inhibitors during degeneration of the nigrostriatal pathway.
    Oberlander C; Euvrard C; Dumont C; Boissier JR
    Eur J Pharmacol; 1979 Dec; 60(2-3):163-70. PubMed ID: 575095
    [No Abstract]   [Full Text] [Related]  

  • 6. The anatomical substrate of the turning behaviour seen after lesions in the nigrostriatal dopamine system.
    Garcia-Munoz M; Patino P; Wright AJ; Arbuthnott GW
    Neuroscience; 1983 Jan; 8(1):87-95. PubMed ID: 6300729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral correlates of dopaminergic supersensitivity.
    Iversen SD; Creese I
    Adv Neurol; 1975; 9():81-92. PubMed ID: 1170717
    [No Abstract]   [Full Text] [Related]  

  • 8. The 6-hydroxydopamine rotational model for the detection of dopamine agonist activity: reliability of effect from different locations of 6-hydroxydopamine.
    Costall B; Naylor RJ; Pycock C
    J Pharm Pharmacol; 1975 Dec; 27(12):943-6. PubMed ID: 2668
    [No Abstract]   [Full Text] [Related]  

  • 9. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants.
    Björklund A; Stenevi U
    Brain Res; 1979 Nov; 177(3):555-60. PubMed ID: 574053
    [No Abstract]   [Full Text] [Related]  

  • 10. Non-specific supersensitivity of striatal dopamine receptors after 6-hydroxydopamine lesion of the nigrostriatal pathway.
    Costall B; Naylor RJ; Pycock C
    Eur J Pharmacol; 1976 Feb; 35(2):276-83. PubMed ID: 942921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The brain's dopamine receptor: labeling with (3H) dopamine and (3H) haloperidol.
    Snyder SH; Creese I; Burt DR
    Psychopharmacol Commun; 1975; 1(6):663-73. PubMed ID: 1241457
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of ethanol on turnover and function of striatal dopamine.
    Lai H; Makous WL; Horita A; Leung H
    Psychopharmacology (Berl); 1979 Mar; 61(1):1-9. PubMed ID: 108711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioural sequelae of dopaminergic degeneration: postsynaptic supersensitivity?
    Creese I; Iversen SD
    Psychopharmacol Bull; 1975 Oct; 11(4):12-3. PubMed ID: 1197588
    [No Abstract]   [Full Text] [Related]  

  • 14. Localization of opiate receptors and enkephalins in the rat striatum in relationship with the nigrostriatal dopaminergic system: lesion studies.
    Pollard H; Llorens C; Schwartz JC; Gros C; Dray F
    Brain Res; 1978 Aug; 151(2):392-8. PubMed ID: 209865
    [No Abstract]   [Full Text] [Related]  

  • 15. Changed eating and locomotor behaviour in the rat after 6-hydroxydopamine lesions to the substantia nigra.
    Brook C; Iversen SD
    Neuropharmacology; 1975 Feb; 14(2):95-105. PubMed ID: 1171387
    [No Abstract]   [Full Text] [Related]  

  • 16. Monoamine oxidase and aldehyde dehydrogenase activity in the striatum of rats after 6-hydroxydopamine lesion of the nigrostriatal pathway.
    Agid Y; Javoy F; Youdim MB
    Br J Pharmacol; 1973 May; 48(1):175-8. PubMed ID: 4724190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proceedings: Differences in circling responses following electrolytic and 6-hydroxydopamine lesions of the nigro-striatal pathway.
    Costall B; Marsden CD; Naylor RJ; Pycock CJ
    Br J Pharmacol; 1975 Oct; 55(2):289P-290P. PubMed ID: 1238135
    [No Abstract]   [Full Text] [Related]  

  • 18. Apomorphine and amphetamine stereotypy after 6-hydroxydopamine lesions of the substantia nigra.
    Price MT; Fibiger HC
    Eur J Pharmacol; 1974 Dec; 29(2):249-52. PubMed ID: 4613562
    [No Abstract]   [Full Text] [Related]  

  • 19. Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
    Ungerstedt U; Ljungberg T; Steg G
    Adv Neurol; 1974; 5():421-6. PubMed ID: 4531217
    [No Abstract]   [Full Text] [Related]  

  • 20. The neurological basis of motor asymmetry following unilateral nigrostriatal lesions in the rat: the effect of secondary superior colliculus lesions.
    Crossman AR; Sambrook MA
    Brain Res; 1978 Dec; 159(1):211-3. PubMed ID: 569529
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.